As dasatinib is a drug already approved in the cancer clinic, the identification that the prometastatic NRG–MMP13 axis is sensitive to dasatinib opens the possibility of incorporating this drug to the armamentarium to fight breast cancer metastatic dissemination. This evidence concerns the gene MMP13 and breast carcinoma.